The purpose of this study is to investigate the effectiveness of an investigational medication in patients with prostate cancer that is PSMA-positive and has spread to other parts of the body. This study focuses on comparing the survival of patients receiving the investigational medication along with the best supportive care to those receiving only the best supportive care. PSMA stands for Prostate-Specific Membrane Antigen, a protein found in high amounts on prostate cancer cells.

Participants in this study will be randomly assigned to different study arms. One group will receive the investigational medication along with standard supportive care, while the other group will receive only the standard supportive care. The study will monitor patients for their survival, disease progression, and any side effects during and after the treatment period. Blood tests will also be conducted to check health indicators.

• Who can participate: Patients aged 18 and older with confirmed prostate cancer, who have undergone orchiectomy or are on ongoing androgen-deprivation therapy with low testosterone levels, are eligible. For detailed criteria, refer to the clinical trial listing.
• Study details: Participants will be randomly assigned to receive either the investigational medication with supportive care or supportive care alone. The investigational medication is not a standard treatment and is being tested for its effects on prostate cancer.
• Study Timelines: The study will last 6 to 10 months.